umeclidinium bromide and vilanterol trifenatate 62.5 ug/1 / 25 ug/1 Medicare Part D Coverage
cover umeclidinium bromide and vilanterol trifenatate
Formulary Tier Distribution
How Medicare Part D plans classify umeclidinium bromide and vilanterol trifenatate. Lower tiers = lower copays.
Find the cheapest plan for umeclidinium bromide and vilanterol trifenatate
Enter your ZIP code to compare every plan in your area side-by-side.
Get umeclidinium bromide and vilanterol trifenatate Delivered to Your Door
Compare prices and get discounts from trusted online pharmacies
DrugCovered may earn commissions from pharmacy purchases. Prices and availability vary. Always consult your doctor before starting or changing medications.
umeclidinium bromide and vilanterol trifenatate Medicare Coverage by State
Coverage rates and average costs vary significantly by state. Click a state to see the specific plans available there.
Alternative Medications in the Same Drug Class
Other drugs in the Bronchodilators that Medicare Part D plans also cover.
Frequently Asked Questions about umeclidinium bromide and vilanterol trifenatate
78% of Medicare Part D plans cover umeclidinium bromide and vilanterol trifenatate. It is most commonly placed on Tier 3. Coverage varies by plan and geographic area.
The median 30-day copay for umeclidinium bromide and vilanterol trifenatate on Medicare Part D is $44.00 at a preferred pharmacy. Costs range from $0.00 to $88.00 depending on the plan.
umeclidinium bromide and vilanterol trifenatate is placed on Tier 3 by most Medicare Part D plans. Lower tier numbers generally mean lower copays.
0% of plans require prior authorization for umeclidinium bromide and vilanterol trifenatate. Prior authorization means your doctor must confirm the drug is medically necessary before the plan will cover it.
Medicare & Health Management Products
As an Amazon Associate, DrugCovered may earn from qualifying purchases. Product recommendations are for informational purposes and do not constitute medical advice.
Coverage statistics based on CMS formulary data for plan year 2026. Data updated regularly. Methodology →